2015
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma
Mohan S, Vander Broek R, Shah S, Eytan D, Pierce M, Carlson S, Coupar J, Zhang J, Cheng H, Chen Z, Van Waes C. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2015, 21: 3946-3956. PMID: 25977343, PMCID: PMC4558307, DOI: 10.1158/1078-0432.ccr-14-3377.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBenzamidesCarcinoma, Squamous CellCell Line, TumorCell ProliferationCell SurvivalCell Transformation, NeoplasticCytokinesDiphenylamineDisease Models, AnimalDrug Resistance, NeoplasmDrug SynergismGene ExpressionGenes, ReporterHead and Neck NeoplasmsHumansInflammation MediatorsMitogen-Activated Protein Kinase KinasesMorpholinesNF-kappa BPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphorylationProtein Kinase InhibitorsSignal TransductionSquamous Cell Carcinoma of Head and NeckTOR Serine-Threonine KinasesTranscription Factor AP-1Transcriptional ActivationTriazinesXenograft Model Antitumor Assays
2013
The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross‐talk, and therapies
Vander Broek R, Mohan S, Eytan D, Chen Z, Van Waes C. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross‐talk, and therapies. Oral Diseases 2013, 21: 815-825. PMID: 24219320, DOI: 10.1111/odi.12206.Peer-Reviewed Original ResearchConceptsAkt/mTOR axisPI3K/Akt/mTOR axisDNA copy number variationsMTOR axisCopy number variationsPI3K/Akt/mTORDysregulation of mRNAsNeck squamous cell carcinomaPI3K/AKT/mTOR pathwayAKT/mTOR pathwayAkt/mTORSquamous cell carcinomaPathway leadCell survivalNumber variationsPI3KMalignant phenotypeMTOR pathwayNormal physiologyCell carcinomaHNSCC casesNeck cancerClinical studiesProtein expressionGenetic aberrations